PetVivo Issues Correction and Replacement Press Release; Sets Fiscal Third Quarter 2026 Conference Call for Tuesday, February 17, 2026 at 5:00 p.m. ET
MWN-AI** Summary
PetVivo Holdings, Inc., through its subsidiary PetVivo Animal Health, has issued a corrected press release on February 10, 2026, superseding a prior announcement regarding its fiscal third quarter 2026 conference call. This newly released information clarifies the details for the upcoming call, now scheduled for Tuesday, February 17, 2026, at 5:00 p.m. ET. The financial results for the quarter ending December 31, 2025, will be disclosed prior to the call, which will include a presentation by the company's management followed by a question-and-answer segment for participants.
Interested individuals can join the conference call using the toll-free dial-in number +1 719 359 4580, and the Conference ID is 82997673848 with a passcode of 956814. For those unable to listen live, a replay of the conference will be available via the company's website.
PetVivo Holdings focuses on innovative biomedical devices and therapeutics, particularly targeting the veterinary market for equines and companion animals. The company’s strategy emphasizes leveraging human medical technology into animal health solutions, expediting the time to market for veterinary devices compared to more stringently regulated pharmaceuticals. PetVivo's flagship products include SPRYNG® with OsteoCushion® technology and PrecisePRP®, both aimed at addressing joint-related conditions in animals.
PetVivo is dedicated to developing a diverse portfolio of veterinary therapies, protected by numerous patents and trade secrets. As a growing company in a niche market, it plans to continue advancing its product offerings while addressing the evolving needs of animal health care. For further details, investors can refer to the company’s investor relations page.
MWN-AI** Analysis
PetVivo Holdings, Inc. (OTCQX: PETV) has recently issued a correction on its February 9 press release announcing the details of its fiscal third quarter 2026 conference call. This retraction raises several considerations for investors monitoring the company’s trajectory in the growing veterinary biomedical market.
The anticipated conference call on February 17, 2026, will likely focus on the company’s performance for the fiscal third quarter ending December 31, 2025. It will provide insights into financial results, product performance, and strategic direction. Investors should pay attention to how management addresses potential challenges, particularly given the market's sensitivity to changes in communications and financial disclosures.
PetVivo's emphasis on leveraging human medical therapies for companion animals presents a unique proposition, but it also carries inherent risks. The comparison with human health care indicates a potentially faster revenue generation timeline for its veterinary devices. However, miscommunications, such as the recent press release retraction, could raise questions about the company’s operational robustness and investor communication strategies.
Key products like SPRYNG® with OsteoCushion® technology and PrecisePRP® indicate a solid product pipeline. Investors should evaluate the market acceptance and performance of these offerings in comparison to competitors. Moreover, the company's strong patent portfolio reinforces its strategic positioning in the veterinary therapeutics landscape, an important factor for sustaining competitive advantages.
The upcoming conference call will be crucial for discerning the company's future. Investors should prioritize listening for updates on revenue growth, product adoption rates, operational challenges, and any forward-looking statements. Given the inherent risks highlighted in PetVivo’s disclosures, critical analysis and due diligence are essential for those considering an investment in this promising yet volatile sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MINNEAPOLIS, MN, US, Feb. 10, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc., in collaboration with its wholly-owned subsidiary PetVivo Animal Health (OTCQX: PETV; OTCID: PETVW), a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, today announced that it is retracting and replacing its previously issued press release dated February 9, 2026 regarding the Company’s fiscal third quarter 2026 conference call.
This press release supersedes in its entirety the prior press release, which should no longer be relied upon.
PetVivo will hold a conference call on Tuesday, February 17, 2026, at 5:00 p.m. Eastern Time to discuss results for the fiscal third quarter ended December 31, 2025. The Company’s financial results will be issued in a press release prior to the conference call.
PetVivo management will host the presentation, followed by a question-and-answer period. The fiscal third quarter 2026 conference call information is as follows:
Date: Tuesday, February 17, 2026
Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific time)
Toll-free dial-in number: +1 719 359 4580
Conference ID: 82997673848
Passcode: 956814
Webcast (live and replay): Click Here
A replay of the webcast will be available through the same link following the conference call.
The conference call webcast replay will also be available via a link in the Investors section of the company’s website at petvivo.com/investors.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQX: PETV; OTCID: PETVW), in cooperation with its wholly-owned subsidiary PetVivo Animal Health, Inc., is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve patents and six trade secrets protect the Company's biomaterials, products, production processes and methods of use. The Company’s lead products SPRYNG® with OsteoCushion® technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP®, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale.
Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216
Forward-Looking commercial Statements
The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2025 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ**
What potential impact could the upcoming fiscal third quarter results announcement have on the trading value of PetVivo Holdings Inc. Warrant PETVW following the conference call on February 17, 2026?
How does PetVivo Holdings Inc. Warrant PETVW compare in terms of market performance with other veterinary biomedical companies focusing on companion animals?
Given the company's strategy to leverage human therapies for animals, how might this influence the financial outlook for PetVivo Holdings Inc. Warrant PETVW in the coming years?
What specific factors from PetVivo Holdings Inc.'s product pipeline should investors consider when evaluating the potential value of PetVivo Holdings Inc. Warrant PETVW?
**MWN-AI FAQ is based on asking OpenAI questions about PetVivo Holdings Inc. Warrant (OTC: PETVW).
NASDAQ: PETVW
PETVW Trading
0.07% G/L:
$0.0344 Last:
5,000 Volume:
$0.034375 Open:
